Hims & Hers Health, Inc. (NYSE:HIMS) Short Interest Update

Hims & Hers Health, Inc. (NYSE:HIMS) was the recipient of a large drop in short interest in September. As of September 15th, there was short interest totalling 26,540,000 shares, a drop of 5.3% from the August 31st total of 28,040,000 shares. Based on an average trading volume of 8,750,000 shares, the short-interest ratio is currently 3.0 days. Currently, 16.2% of the company’s shares are sold short.

Hims & Hers Health Trading Up 3.7 %

Shares of HIMS stock traded up $0.66 on Monday, reaching $18.43. 7,011,084 shares of the company’s stock were exchanged, compared to its average volume of 7,689,988. The company’s fifty day simple moving average is $16.89 and its 200 day simple moving average is $17.22. The stock has a market capitalization of $3.96 billion, a PE ratio of -1,842.50 and a beta of 1.05. Hims & Hers Health has a 52 week low of $5.65 and a 52 week high of $25.74.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 5th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The firm had revenue of $315.65 million during the quarter, compared to analyst estimates of $302.43 million. During the same quarter in the previous year, the business posted ($0.03) EPS. Hims & Hers Health’s revenue was up 51.8% on a year-over-year basis. As a group, sell-side analysts predict that Hims & Hers Health will post 0.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HIMS has been the topic of several recent research reports. TD Cowen upped their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Needham & Company LLC began coverage on Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target on the stock. Truist Financial upped their price objective on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, July 18th. Finally, Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a report on Friday, August 9th. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health has an average rating of “Moderate Buy” and a consensus target price of $19.86.

Insider Transactions at Hims & Hers Health

In other news, insider Soleil Boughton sold 2,335 shares of the company’s stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $20.28, for a total transaction of $47,353.80. Following the transaction, the insider now directly owns 169,144 shares of the company’s stock, valued at $3,430,240.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Soleil Boughton sold 2,335 shares of the stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $20.28, for a total value of $47,353.80. Following the completion of the sale, the insider now directly owns 169,144 shares of the company’s stock, valued at approximately $3,430,240.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Michael Chi sold 2,054 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $22.00, for a total transaction of $45,188.00. Following the completion of the sale, the insider now owns 185,326 shares of the company’s stock, valued at approximately $4,077,172. The disclosure for this sale can be found here. In the last ninety days, insiders sold 731,473 shares of company stock valued at $12,671,277. Corporate insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several large investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its holdings in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the last quarter. Quest Partners LLC raised its position in Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after acquiring an additional 3,507 shares in the last quarter. Van ECK Associates Corp acquired a new position in Hims & Hers Health in the second quarter valued at approximately $111,000. Amalgamated Bank increased its holdings in shares of Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after purchasing an additional 2,354 shares in the last quarter. Finally, Daiwa Securities Group Inc. purchased a new position in shares of Hims & Hers Health during the 2nd quarter valued at approximately $142,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.